Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 15/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826156 | 1.00 | TNF (0.48) | TNFMEN1KMT2APDE4APDE4B | |
| SCHEMBL27942400 | 0.90 | TNF (0.45) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1609809 | 0.87 | PDE4B (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15869361 | 0.87 | PDE4B (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15862507 | 0.87 | PDE4B (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1585249 | 0.87 | PDE4B (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15869366 | 0.87 | PDE4B (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17085033 | 0.87 | PDE4B (0.56) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3523757 | 0.86 | UTS2R (0.47) | TNFMEN1KMT2APDE4APDE4B | |
| SCHEMBL1829132 | 0.86 | PDE4A (0.54) | TNFMEN1KMT2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076369-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076369-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1606256-B1 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | CELGENE CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | CELGENE CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7662847-B2 | Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors | CELGENE CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662847-B2 | Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors | CELGENE CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1606256-A2 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050203090-A1 | Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds | AMGEN INC. | 2005-09-15 | — | — | US | disclosed |
| US-6911464-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | AMGEN INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080422-A2 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE12, PDE4B | TNF 2494/4885MEN1 3906/4885KMT2A 2324/4885 |
| US-20050203090-A1 | Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds | PDE4A, PDE4B, PDE7A | TNF 2208/4885MEN1 3561/4885KMT2A 2008/4885 |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | PDE4A, PDE12, PDE4B | TNF 2494/4885MEN1 3906/4885KMT2A 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.